Mannatech, Incorporated (NASDAQ:MTEX – Get Rating)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $20.56 and traded as low as $16.24. Mannatech shares last traded at $16.24, with a volume of 871 shares trading hands.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on MTEX shares. StockNews.com started coverage on shares of Mannatech in a report on Tuesday. They set a “buy” rating on the stock. TheStreet upgraded shares of Mannatech from a “c+” rating to a “b-” rating in a report on Thursday, October 13th.
Mannatech Price Performance
The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.74 and a current ratio of 1.27. The firm has a market cap of $29.37 million, a price-to-earnings ratio of 6.99 and a beta of 1.17. The company’s fifty day moving average is $19.66 and its two-hundred day moving average is $20.54.
Mannatech Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, December 28th. Investors of record on Wednesday, December 14th were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 5.06%. The ex-dividend date of this dividend was Tuesday, December 13th. Mannatech’s dividend payout ratio (DPR) is 35.40%.
Insider Buying and Selling
In related news, Director Kevin Andrew Robbins sold 1,500 shares of Mannatech stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $22.00, for a total transaction of $33,000.00. Following the sale, the director now owns 11,531 shares of the company’s stock, valued at approximately $253,682. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Kevin Andrew Robbins sold 1,500 shares of Mannatech stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $22.00, for a total transaction of $33,000.00. Following the sale, the director now owns 11,531 shares of the company’s stock, valued at approximately $253,682. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Alfredo Bala sold 3,500 shares of the business’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $19.69, for a total transaction of $68,915.00. Following the completion of the sale, the chief executive officer now directly owns 4,406 shares of the company’s stock, valued at approximately $86,754.14. The disclosure for this sale can be found here. 50.00% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Mannatech
A hedge fund recently bought a new stake in Mannatech stock. IFG Advisory LLC bought a new position in Mannatech, Incorporated (NASDAQ:MTEX – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 20,090 shares of the company’s stock, valued at approximately $417,000. IFG Advisory LLC owned about 1.05% of Mannatech as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 24.90% of the company’s stock.
About Mannatech
Mannatech, Inc engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L.
Read More
- Get a free copy of the StockNews.com research report on Mannatech (MTEX)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.